ESMO Guideline 2015

European Society for Medical Oncology recommends EndoPredict for breast cancer patients.

(DGAP-Media / 15.09.2015 / 15:22)

In its recently published "Clinical Practice Guidelines", the European
Society for Medical Oncology (ESMO) advocates the use of the EndoPredict
gene expression test for primary diagnosis in breast cancer patients. The
test should be used in women for whom no clear indication for or against
adjuvant chemotherapy can be established. In these women, the test can
predict the individual risk of recurrence and the benefit of chemotherapy,
confirms the scientific body.

EndoPredict is a second generation gene expression test covering not only
disease-relevant tumour genes but also classical clinical prognostic
factors (tumour size and nodal status). Based on the test result, the
patients can be assigned to a high or low risk group. High risk patients
are recommended to undergo chemotherapy because of the increased
therapeutic benefit. Low risk patients can do without the stressful
procedure.

About 60 % of the tested patients can be assigned to the low risk group.
Without the test, the majority of these women would receive chemotherapy.
The additional information provided by the EndoPredict test helps to avoid
overtreatment and serious side effects.

The test can be performed decentrally in the local pathology department. It
is already used in Europe and worldwide on a regular basis to determine
breast cancer patients' prognoses. EndoPredict is produced by Sividon
Diagnostics, a company based in Germany (Cologne) and specialised in the
development of molecular diagnostic tests. "Women in an increasing number
of countries can benefit from EndoPredict since the introduction of the
test in 2011", says PD Dr. Ralf Kronenwett, Head of Research and
Development at Sividon. "The test has now become a generally accepted part
of treatment guidelines, not only in Germany but also internationally."

In addition to the new ESMO Guidelines, EndoPredict is already recommended
by the therapy guidelines of the Working Group for Gynaecological Oncology
(AGO) and the St. Gallen Consensus Conference.

The "Primary breast cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up" have been published at the following
link: http://annonc.oxfordjournals.org/content/26/suppl_5/v8.full.pdf+html



Sividon Diagnostics GmbH was founded in July 2010 as a management buyout
from Siemens Healthcare Diagnostics Products in Cologne, Germany. The
company aims to sustainably increase the quality of therapy-accompanying
diagnostics in oncology. EndoPredict(R), the first diagnostic test from
Sividon, has been available since 2011.

Further information is available at www.sividon.com or www.endopredict.com.


End of Media Release

---------------------------------------------------------------------

Issuer: Sividon Diagnostics GmbH
Key word(s): Health

15.09.2015 Dissemination of a Press Release, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


394711 15.09.2015